AI Article Synopsis
- Endothelial Progenitor Cells (EPC) were identified in 1997 and have been extensively researched for their role in heart damage and repair.
- Their definition and mechanisms are still not fully understood, but they are influenced by cardiovascular risk factors and contribute to assessing cardiovascular risk.
- Understanding EPCs could lead to new treatments for cardiovascular disease, and this review summarizes existing research on their clinical relevance in cardiology.
Article Abstract
Endothelial Progenitor Cells (EPC) were first described in 1997 and have since been the subject of numerous investigative studies exploring the potential of these cells in the process of cardiovascular damage and repair. Whilst their exact definition and mechanism of action remains unclear, they are directly influenced by different cardiovascular risk factors and have a definite role to play in defining cardiovascular risk. Furthermore, EPCs may have important therapeutic implications and further understanding of their pathophysiology has enabled us to explore new possibilities in the management of cardiovascular disease. This review article aims to provide an overview of the vast literature on EPCs in relation to clinical cardiology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834645 | PMC |
| http://dx.doi.org/10.1186/2040-2384-2-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!